Comprehensive evaluation of xylometazoline hydrochloride formulations: Ex-vivo and in-vitro studies.

Autor: Tuncay Tanriverdi S; Faculty of Pharmacy, Department of Pharmaceutical Technology, Ege University, Bornova, 35100 Izmir, Turkiye. Electronic address: sakinetuncay@windowslive.com., Gokce EH; Faculty of Pharmacy, Department of Pharmaceutical Technology, Ege University, Bornova, 35100 Izmir, Turkiye. Electronic address: evren.homan.gokce@ege.edu.tr., Sušanj I; Jadran Galenski Laboratorij, Svilno 20, Rijeka, Croatia. Electronic address: ivan.susanj@jglpharma.com., Simić L; Jadran Galenski Laboratorij, Svilno 20, Rijeka, Croatia. Electronic address: laura.simic@jglpharma.com., Vukelić K; Jadran Galenski Laboratorij, Svilno 20, Rijeka, Croatia. Electronic address: karina.vukelic@jglpharma.com., Knežević Z; Jadran Galenski Laboratorij, Svilno 20, Rijeka, Croatia. Electronic address: zdravka.knezevic@jglpharma.com., Ilhan P; Faculty of Engineering, Department of Bioengineering, Ege University, Bornova, 35100 Izmir, Turkiye. Electronic address: coruk.pelin@gmail.com., Sendemir A; Faculty of Engineering, Department of Bioengineering, Ege University, Bornova, 35100 Izmir, Turkiye. Electronic address: aylin.sendemir@ege.edu.tr., Ozer O; Faculty of Pharmacy, Department of Pharmaceutical Technology, Ege University, Bornova, 35100 Izmir, Turkiye. Electronic address: ozgen.ozer@ege.edu.tr.
Jazyk: angličtina
Zdroj: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V [Eur J Pharm Biopharm] 2024 Oct; Vol. 203, pp. 114466. Date of Electronic Publication: 2024 Aug 22.
DOI: 10.1016/j.ejpb.2024.114466
Abstrakt: Xylometazoline is a well-established nasal decongestant that has been used alone and in combination with dexpanthenol as an over the counter (OTC) medicine. Considering the possibility of further improvement of xylometazoline nasal formulations, hyaluronic acid (HA) was evaluated as an additional ingredient. The aim of this study was to investigate the permeation, mucosal retention, and mucoadhesion properties of a new xylometazoline-HA [Xylo-HA] formulation ex vivo and to explore the potential benefits of incorporating HA in the formulation in vitro. Sheep nasal mucosa was used in the ex vivo study, where Xylo-HA was compared with xylometazoline alone [Xylo-Mono], and in combination with dexpanthenol [Xylo-Dex] to understand the impact of formulation changes. The permeation of xylometazoline was generally low (Xylo-Mono 11.14 ± 4.75 %, Xylo-HA 14.57 ± 5.72 % and Xylo-Dex 11.00 ± 3.05 % of the applied dose). The steady state fluxes of xylometazoline were determined as 12.64 ± 3.52 μg/cm 2 h, 14.94 ± 3.38 μg/cm 2 h and 12.19 ± 2.05 μg/cm 2 h for Xylo-Mono, Xylo-HA and Xylo-Dex, respectively. No significant differences were observed between the formulations in the permeation nor mucosal retention studies (p > 0.05 for all), while Xylo-HA exhibited superior mucoadhesive proprieties (p < 0.05 for all). The effects on wound healing and barrier integrity of the three xylometazoline formulations were tested in vitro on HaCaT cells. To better elucidate the role of HA, an additional HA formulation without xylometazoline was prepared (HA-Mono). A scratch test was performed to evaluate wound healing, revealing that the test formulations did not achieve complete wound closure within 72 h and demonstrated a similar effect at the end of the testing period. To assess the effect on barrier integrity, cells were treated for 5 days with daily measurements of transepithelial electrical resistance (TEER). At the end of the experiment, Xylo-Dex showed a moderate 14 % increase in TEER, while Xylo-Mono did not significantly affect this parameter. TEER rose by 951 % in the Xylo-HA, and by 10497 % in the HA group, suggesting that incorporating HA led to enhanced barrier function. Further clinical studies are recommended to better understand the clinical implications and efficacy of the Xylo-HA formulation, with particular focus on the role of HA.
(Copyright © 2024 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: